Xcout Intel
Spago Nanomedical
Spago Nanomedical is a clinical-stage pharmaceutical company that develops precision nanomedicine products for the diagnosis and treatment of cancer and other severe diseases. Its pipeline includes Tumorad, a targeted radionuclide therapy for various cancers, and SpagoPix, a polymeric contrast agent designed to improve the precision of MRI diagnostics.
Subscribe to see Spago Nanomedical’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Spago Nanomedical at a glance
Spago Nanomedical is a health care company headquartered in Sweden. Xcout tracks 10 named people at Spago Nanomedical, including Mats Hansen (Chief Executive Officer (CEO)).
Spago Nanomedical leadership
- Mats HansenChief Executive Officer (CEO)
- Hanna OlssonChief Financial Officer (CFO)
- Paul HargreavesChief Development Officer (CDO)
- Alan RaffenspergerChairman of the Board
- Kari GrønåsBoard Member
- Mikael LönnBoard member
4 more named people on record for Spago Nanomedical, with roles, board committees and tenure — see the full roster →
Spago Nanomedical competitors
A few of Spago Nanomedical's closest competitors — see the full list of competitors and alternatives →
BAMF Health provides molecular imaging and radiopharmaceutical therapy services for patients suffering from conditions such as cancer and Alzheimer’s disease. The company utilizes advanced scanning technologies, including total-body PET/CT and whole-body MRI, to deliver intelligence-based precision medicine and personalized treatment plans.
ImaginAb, Inc. is a global biotechnology company headquartered in California, with operations in Los Angeles and San Diego. It focuses on developing next-generation imaging and radiopharmaceutical products for cancer immunology.
ABSCINT is a clinical-stage biotechnology company that develops platform production processes for rapid creation of cold kits for molecular imaging in oncology and immunology. Headquartered in Belgium, the privately held firm focuses on innovative diagnostic and therapeutic applications using single-domain antibodies.
On Target Laboratories, Inc. is a biotechnology company founded in 2010 and headquartered in West Lafayette, Indiana. It discovers and develops targeted intraoperative molecular imaging agents to illuminate cancer during surgery.
PD Theranostics, Inc. (operating as United Theranostics) provides molecular imaging and precision radiopharmaceutical therapy for cancer patients, specializing in treatments for prostate cancer, neuroendocrine tumors, and thyroid cancer. The company utilizes advanced diagnostics such as PET and SPECT scans combined with targeted radiopharmaceuticals to deliver personalized, outpatient treatment plans. Additionally, they participate in clinical trials and collaborate with referring providers to offer innovative cancer care options.
Get Spago Nanomedical's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Spago Nanomedical in Xcout Intel
- 10 named people with titles, LinkedIn and board committees
- The full competitor set, tracking, exports and API access